# US 10,246,414 B2 · Allosteric modulators of CB1 cannabinoid receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,246,414 B2
- Document ID: US10246414B2
- Status: Granted
- Kind: B2
- Application number: 15/416,311
- Filed: 2017-01-26
- Published: 2017-07-13
- Granted: 2019-04-02
- Earliest claimed: 2012-01-05
- Assignees: Northeastern University
- Applicants: Northeastern University
- Inventors: Ganeshsingh A. Thakur; Pushkar M. Kulkarni
- Web page: https://patentgrep.com/patent/US10246414B2

## CPC

- C07D 209/10: with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D 209/14: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (CB1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the CB1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.

## Claims

### Claim 1

A pharmaceutical composition for treatment of Huntington's disease, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
and a pharmaceutically-acceptable carrier or diluent.

### Claim 2

A pharmaceutical composition for treatment of Huntington's disease or glaucoma, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
and a pharmaceutically acceptable carrier or diluent.

### Claim 3

A pharmaceutical composition for treatment of Huntington's disease, pain, neuropathic pain, glaucoma, post-traumatic stress disorder, or epileptic seizure, the composition comprising an effective amount of a compound having the following structure, or a pharmaceutically acceptable salt thereof:
and a pharmaceutically acceptable carrier or diluent.